Stromal re-engineering to treat pancreas cancer

Carcinogenesis

Volumn 35, Issue 7, 2014, Pages

  Stromnes, Ingunn M ^a,c   DelGiorno, Kathleen E ^a   Greenberg, Philip D ^a,b,c   Hingorani, Sunil R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Immunotherapy; Interstitial fluid pressure; Pancreatic cancer; Pancreatic ductal adenocarcinoma; Stromal resistance

Indexed keywords

HYALURONIC ACID; OSTEONECTIN;

ARTICLE; BONE MARROW CELL; CANCER THERAPY; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; GENETICALLY ENGINEERED MOUSE STRAIN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MESENCHYME; MESENCHYME CELL; PANCREAS ADENOCARCINOMA; PARACRINE SIGNALING; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STROMA; TISSUE ENGINEERING; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; HUMAN; MOUSE; PANCREAS TUMOR; PATHOLOGY; REVIEW; STROMA CELL;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; MICE; PANCREATIC NEOPLASMS; STROMAL CELLS; TISSUE ENGINEERING;

EID: 84903991824     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu115     Document Type: Article

References (149)

1. Hanahan, D., et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-74.
2. Maitra, A., et al. (2008) Pancreatic cancer. Annu Rev Pathol, 3, 157-88.
3. Ino, Y., et al. (2013) Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer, 108, 914-23.
4. Cheng, X.B., et al. (2013) Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma. PLoS One, 8, e80765.
5. Provenzano, P.P., et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell, 21, 418-29.
6. Jacobetz, M.A., et al. (2013) Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut, 62, 112-20.
7. Olive, K.P., et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324, 1457-61.
8. Beatty, G.L., et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science, 331, 1612-6.
9. Kraman, M., et al. (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330, 827-30.
10. Hingorani, S.R., et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4, 437-50.
11. Aguirre, A.J., et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev, 17, 3112-26.
12. Hingorani, S.R., et al. (2005) Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 7, 469-83.
13. Guerra, C., et al. (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell, 11, 291-302.
14. Collins, M.A., et al. (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest, 122, 639-53.
15. Ying, H., et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149, 656-70.
16. Hruban, R.H., et al. (2006) Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res, 66, 95-106.
17. Perez-Mancera, P.A., et al. (2012) What we have learned about pancreatic cancer from mouse models. Gastroenterology, 142, 1079-92.
18. Bailey, J.M., et al. (2014) The Secret Origins and Surprising Fates of Pancreas Tumors. Carcinogenesis.
19. Clark, C.E., et al. (2007) Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res, 67, 9518-27.
20. Stromnes, I.M., et al. (2014) Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut.
21. Sanford, D.E., et al. (2013) Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis. Clin Cancer Res, 19, 3404-15.
22. Hiraoka, N., et al. (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res, 12, 5423-34.
23. Ryschich, E., et al. (2005) Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res, 11, 498-504.
24. Gabrilovich, D.I., et al. (2007) The terminology issue for myeloid-derived suppressor cells. Cancer Res, 67, 425; author reply 426.
25. Talmadge, J.E., et al. (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer, 13, 739-52.
26. Bayne, L.J., et al. (2012) Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell, 21, 822-35.
27. Pylayeva-Gupta, Y., et al. (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer cell, 21, 836-47.
28. Gabrilovich, D.I., et al. (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nature reviews. Immunology, 9, 162-74.
29. Youn, J.I., et al. (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 181, 5791-802.
30. Diaz-Montero, C.M., et al. (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother, 58, 49-59.
31. Porembka, M.R., et al. (2012) Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer immunology, immunotherapy: CII.
32. Sanford, D.E., et al. (2013) A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. J Cancer Ther, 4, 797-803.
33. Hogquist, K.A., et al. (2005) Central tolerance: learning self-control in the thymus. Nat Rev Immunol, 5, 772-82.
34. Sakaguchi, S. (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol, 22, 531-62.
35. Witkiewicz, A., et al. (2008) Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg, 206, 849-54; discussion 854-6.
36. Ikemoto, T., et al. (2013) Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood. Pancreas, 42, 130-4.
37. von Bernstorff, W., et al. (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clinical cancer research: An official journal of the American Association for Cancer Research, 7, 925s-932s.
38. Akasaki, Y., et al. (2004) Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol, 173, 4352-9.
39. Bergmann, C., et al. (2007) Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res, 67, 8865-73.
40. Mougiakakos, D., et al. (2010) Regulatory T cells in cancer. Adv Cancer Res, 107, 57-117.
41. Liyanage, U.K., et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of immunology, 169, 2756-61.
42. Huang, C.T., et al. (2004) Role of LAG-3 in regulatory T cells. Immunity, 21, 503-13.
43. Collison, L.W., et al. (2010) IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol, 11, 1093-101.
44. North, R.J. (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med, 155, 1063-74.
45. Ercolini, A.M., et al. (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med, 201, 1591-602.
46. Lutsiak, M.E., et al. (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 105, 2862-8.
47. Dudley, M.E., et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, NY), 298, 850-4.
48. Dudley, M.E., et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, 2346-57.
49. Rech, A.J., et al. (2009) Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci, 1174, 99-106.
50. Rech, A.J., et al. (2012) CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med, 4, 134ra62.
51. Mahnke, K., et al. (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer, 120, 2723-33.
52. Aida, K., et al. (2013) Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-alpha gene therapy for pancreatic cancer. Cancer Sci.
53. Tan, M.C., et al. (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. Journal of immunology, 182, 1746-55.
54. Sugiyama, D., et al. (2013) Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A, 110, 17945-50.
55. Chen, W., et al. (2008) The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol, 181, 5396-404.
56. Royal, R.E., et al. (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. Journal of immunotherapy, 33, 828-33.
57. Le, D.T., et al. (2013) Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. J Immunother, 36, 382-9.
58. Delgoffe, G.M., et al. (2013) Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature, 501, 252-6.
59. Muller, M.W., et al. (2007) Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. Int J Cancer, 121, 2421-33.
60. Joyce, J.A., et al. (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer, 9, 239-52.
61. Liou, G.Y., et al. (2013) Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J Cell Biol, 202, 563-77.
62. De Monte, L., et al. (2011) Intratumor T helper type 2 cell infiltrate correlates with cancerassociated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med, 208, 469-78.
63. Ridge, J.P., et al. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature, 393, 474-8.
64. Bennett, S.R., et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature, 393, 478-80.
65. French, R.R., et al. (2007) Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood, 109, 4810-5.
66. De Palma, M., et al. (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell, 23, 277-86.
67. Mitchem, J.B., et al. (2013) Targeting tumor-infiltrating macrophages decreases tumorinitiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res, 73, 1128-41.
68. Weizman, N., et al. (2013) Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene.
69. Zitvogel, L., et al. (2013) Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity, 39, 74-88.
70. Biankin, A.V., et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491, 399-405.
71. Vogelstein, B., et al. (2013) Cancer genome landscapes. Science, 339, 1546-58.
72. Cifola, I., et al. (2013) Comprehensive genomic characterization of cutaneous malignant melanoma cell lines derived from metastatic lesions by whole-exome sequencing and SNP array profiling. PloS one, 8, e63597.
73. Govindan, R., et al. (2012) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 150, 1121-34.
74. Hodi, F.S., et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363, 711-23.
75. Topalian, S.L., et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine, 366, 2443-54.
76. Thomas, A.M., et al. (2004) Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med, 200, 297-306.
77. Feig, C., et al. (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A, 110, 20212-7.
78. Stromnes, I.M., et al. (2014) Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunological reviews, 257, 1-20.
79. Kerkar, S.P., et al. (2011) IL-12 triggers a programmatic change in dysfunctional myeloidderived cells within mouse tumors. J Clin Invest, 121, 4746-57.
80. Liu, R.B., et al. (2013) IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc Natl Acad Sci U S A, 110, 8158-63.
81. Bachem, M.G., et al. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology, 128, 907-21.
82. Ene-Obong, A., et al. (2013) Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology, 145, 1121-32.
83. Rhim, A.D., et al. (2014) Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell.
84. Froeling, F.E., et al. (2011) Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-beta-catenin signaling to slow tumor progression. Gastroenterology, 141, 1486-97, 1497 e1-14.
85. Sherman, M.H., et al. (2012) Nuclear receptors as modulators of the tumor microenvironment. Cancer Prev Res (Phila), 5, 3-10.
86. Iclozan, C., et al. (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer immunology, immunotherapy: CII, 62, 909-18.
87. Abramovitch, S., et al. (2011) Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut, 60, 1728-37.
88. Ding, N., et al. (2013) A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell, 153, 601-13.
89. Ito, I., et al. (2013) A nonclassical vitamin D receptor pathway suppresses renal fibrosis. J Clin Invest, 123, 4579-94.
90. Cohen, S.J., et al. (2008) Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas, 37, 154-8.
91. Lee, H.O., et al. (2011) FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer, 11, 245.
92. Tran, E., et al. (2013) Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med, 210, 1125-35.
93. Schuberth, P.C., et al. (2013) Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med, 11, 187.
94. Azab, A.K., et al. (2009) CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 113, 4341-51.
95. Obermajer, N., et al. (2011) PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res, 71, 7463-70.
96. Phillips, R.J., et al. (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest, 114, 438-46.
97. Reilkoff, R.A., et al. (2011) Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol, 11, 427-35.
98. Devine, S.M., et al. (2004) Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol, 22, 1095-102.
99. Ozdemir, B.C., et al. (2014) Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell.
100. Hirota, K., et al. (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nature immunology, 12, 255-63.
101. Theocharis, A.D., et al. (2000) Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta, 1502, 201-6.
102. Fraser, J.R., et al. (1997) Hyaluronan: its nature, distribution, functions and turnover. J Intern Med, 242, 27-33.
103. Brace, R.A., et al. (1979) Interstitial fluid pressure: capsule, free fluid, gel fluid, and gel absorption pressure in subcutaneous tissue. Microvasc Res, 18, 217-28.
104. DelGiorno, K.E., et al. (2014) Interstitial pressure and vascular collapse in pancreas cancer: fluids and solids, measurement and meaning. Cancer Cell, in press.
105. Brace, R.A. (1981) Progress toward resolving the controversy of positive Vs. negative interstitial fluid pressure. Circ Res, 49, 281-97.
106. Krause, W.E., et al. (2001) Rheology of sodium hyaluronate under physiological conditions. Biomacromolecules, 2, 65-9.
107. Provenzano, P.P., et al. (2013) Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer, 108, 1-8.
108. Boucher, Y., et al. (1992) Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res, 52, 5110-4.
109. Wiederhielm, C.A., et al. (1964) Pulsatile Pressures in the Microcirculation of Frog's Mesentery. Am J Physiol, 207, 173-6.
110. Fadnes, H.O., et al. (1977) Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res, 14, 27-36.
111. Jain, R.K. (1987) Transport of molecules across tumor vasculature. Cancer Metastasis Rev, 6, 559-93.
112. Guyton, A.C. (1963) A concept of negative interstitial pressure based on pressures in implanted perforated capsules. Circ Res, 12, 399-414.
113. Zimmer, H.G., et al. (1998) Technology and application of ultraminiature catheter pressure transducers. Can J Cardiol, 14, 1259-66.
114. Ozerdem, U., et al. (2005) A simple method for measuring interstitial fluid pressure in cancer tissues. Microvasc Res, 70, 116-20.
115. Itano, N., et al. (2002) Mammalian hyaluronan synthases. IUBMB Life, 54, 195-9.
116. Agren, U.M., et al. (1997) Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radic Biol Med, 23, 996-1001.
117. Jiang, D., et al. (2007) Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol, 23, 435-61.
118. Stern, R., et al. (2006) Hyaluronan fragments: an information-rich system. Eur J Cell Biol, 85, 699-715.
119. Maharjan, A.S., et al. (2011) High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation. PLoS One, 6, e26078.
120. Termeer, C.C., et al. (2000) Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol, 165, 1863-70.
121. Scheibner, K.A., et al. (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol, 177, 1272-81.
122. Campo, G.M., et al. (2010) Molecular size hyaluronan differently modulates toll-like receptor-4 in LPS-induced inflammation in mouse chondrocytes. Biochimie, 92, 204-15.
123. Bollyky, P.L., et al. (2007) Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol, 179, 744-7.
124. Bollyky, P.L., et al. (2009) Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells. J Leukoc Biol, 86, 567-72.
125. Bollyky, P.L., et al. (2011) ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A, 108, 7938-43.
126. Toole, B.P. (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer, 4, 528-39.
127. Zhou, G., et al. (2012) Detection and clinical significance of CD44v6 and integrin-beta1 in pancreatic cancer patients using a triplex real-time RT-PCR assay. Appl Biochem Biotechnol, 167, 2257-68.
128. Li, L., et al. (2014) Antibody Against CD44s Inhibits Pancreatic Tumor Initiation and Postradiation Recurrence in Mice. Gastroenterology.
129. Du, Y.C., et al. (2011) Receptor for hyaluronan-mediated motility isoform B promotes liver metastasis in a mouse model of multistep tumorigenesis and a tail vein assay for metastasis. Proc Natl Acad Sci U S A, 108, 16753-8.
130. Imamura, T., et al. (1995) Quantitative analysis of collagen and collagen subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic pancreatitis, and alcoholic chronic pancreatitis. Pancreas, 11, 357-64.
131. Egeblad, M., et al. (2010) Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol, 22, 697-706.
132. Gade, T.P., et al. (2009) Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin Cancer Res, 15, 247-55.
133. Von Hoff, D.D., et al. (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 369, 1691-703.
134. Commisso, C., et al. (2013) Macropinocytosis of protein is an amino acid supply route in Rastransformed cells. Nature, 497, 633-7.
135. Infante, J.R., et al. (2007) Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol, 25, 319-25.
136. Neesse, A., et al. (2013) SPARC independent drug delivery and antitumour effects of nabpaclitaxel in genetically engineered mice. Gut.
137. Neesse, A., et al. (2013) CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A, 110, 12325-30.
138. Skandalis, S.S., et al. (2006) The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim Biophys Acta, 1760, 1217-25.
139. Ricciardelli, C., et al. (1999) Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res, 59, 2324-8.
140. Koninger, J., et al. (2004) Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun, 322, 943-9. Peer Review 32
141. Sakko, A.J., et al. (2001) Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res, 61, 926-30.
142. Ryschich, E., et al. (2009) Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer. Pancreas, 38, 804-10.
143. Santra, M., et al. (1995) De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci U S A, 92, 7016-20.
144. Nash, M.A., et al. (1999) In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res, 59, 6192-6.
145. van der Zee, J.A., et al. (2012) Tumour basement membrane laminin expression predicts outcome following curative resection of pancreatic head cancer. Br J Cancer, 107, 1153-8.
146. Provenzano, P.P., et al. (2013) Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. British journal of cancer, 108, 1-8.
147. Singh, M., et al. (2012) Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol, 30, 648-57.
148. Conroy, T., et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 364, 1817-25.
149. Von Hoff, D.D., et al. (2014) Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med, 370, 479-80.